Pfizer’s CEO says “it’s a question of days, not weeks” before the company and German partner BioNTech submit data to United States regulators for federal authorisation of a Covid-19 vaccine for children aged five to 11.

Pfizer said last week that its vaccine works for that age group and that it tested a much lower dose of the vaccine that’s already available for anyone 12 and older. The company said that after children aged five to 11 got their second dose during testing, they developed coronavirus-fighting antibody levels just as strong as teenagers and young adults getting the regular-strength shots, AP reported.

Pfizer CEO Albert Bourla said that if the Food and Drug Administration approves the company’s application, “we will be ready with our manufacturing to provide this new formulation of the vaccine.”